Oligonucleotide‐based microarray for DNA methylation analysis: Principles and applications
- 2 December 2002
- journal article
- review article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 88 (1) , 138-143
- https://doi.org/10.1002/jcb.10313
Abstract
Gene silencing via promoter CpG island hypermethylation offers tumor cells growth advantages. This epigenetic event is pharmacologically reversible, and uncovering a unique set of methylation‐silenced genes in tumor cells can bring a new avenue to cancer treatment. However, high‐throughput tools capable of surveying the methylation status of multiple gene promoters are needed for this discovery process. Herein we describe an oligonucleotide‐based microarray technique that is both versatile and sensitive in revealing hypermethylation in defined regions of the genome. DNA samples are bisulfite‐treated and PCR‐amplified to distinguish CpG dinucleotides that are methylated from those that are not. Fluorescently labeled PCR products are hybridized to arrayed oligonucleotides that can discriminate between methylated and unmethylated alleles in regions of interest. Using this technique, two clinical subtypes of non‐Hodgkin's lymphomas, mantle cell lymphoma, and grades I/II follicular lymphoma, were further separated based on the differential methylation profiles of several gene promoters. Work is underway in our laboratory to extend the interrogation power of this microarray system in multiple candidate genes. This novel tool, therefore, holds promise to monitor the outcome of various epigenetic therapies on cancer patients.Keywords
This publication has 17 references indexed in Scilit:
- Tumour class prediction and discovery by microarray-based DNA methylation analysisNucleic Acids Research, 2002
- DNA methylation patterns and epigenetic memoryGenes & Development, 2002
- Methylation-Specific Oligonucleotide Microarray: A New Potential for High-Throughput Methylation AnalysisGenome Research, 2001
- Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential22Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; Cy, Cyanine; DLCL, diffuse large cell lymphoma; dNTPs, deoxyribonucleotides; ESTs, expressed sequence tags; mRNA, messenger RNA; NHL, non-Hodgkin’s lymphoma; ORF, open reading frame; RT-PCR, reverse transcription-polymerase chain reaction; and 17AAG, 17-allylamino,17-demethoxygeldanamycin.Biochemical Pharmacology, 2001
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- Cancer-specific region of hypermethylation identified within the HIC1 putative tumour suppressor gene in acute myeloid leukaemiaLeukemia, 1999
- Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cellsOncogene, 1998
- High sensitivity mapping of methylated cytosinesNucleic Acids Research, 1994
- High levels of De Novo methylation and altered chromatin structure at CpG islands in cell linesCell, 1990
- CpG-rich islands and the function of DNA methylationNature, 1986